Current Medicinal Chemistry

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

Back

Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement

(E-pub Ahead of Print)

Author(s): Sandra María Martín-Guerreroa, Josefa Leóna, Rosa Quiles-Pereza, Laura Belmonte, David Martin-Oliva, Ángeles Ruiz-Extremera, Javier Salmerón, José Antonio Muñoz-Gámez.

Abstract:

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.

Keywords: Biomarker, Carcinogenesis, gastrointestinal cancer, PARP inhibitors, poly (ADP-ribose) polymerase-1 (PARP-1), synthetic lethality.

Rights & PermissionsPrintExport

Article Details

VOLUME: 24
Year: 2017
(E-pub Ahead of Print)
DOI: 10.2174/0929867324666170316115039
Price: $95